Considerations on the performance of immunohistochemistry for mismatch repair gene proteins in cases of sebaceous neoplasms and keratoacanthomas with reference to muir-torre syndrome

American Journal of Dermatopathology

Volumn 34, Issue 4, 2012, Pages 416-422

  Fernandez Flores, Angel ^a  

^a HOSPITAL EL BIERZO   (Spain)

Author keywords

BRAF; hereditary nonpoliposis colorectal cancer; Lynch; MLH1; MSH2; MSH6; Muir torre syndrome; PMS2; sebaceoacanthoma; sebaceous adenoma; sebaceous carcinoma; sebaceous hyperplasia

Indexed keywords

B RAF KINASE; MISMATCH REPAIR PROTEIN; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

CANCER EPIDEMIOLOGY; DOMINANT INHERITANCE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; KERATOACANTHOMA; MICROSATELLITE INSTABILITY; MUIR TORRE SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEBACEOUS GLAND TUMOR; SKIN BIOPSY; SOMATIC MUTATION;

BIOPSY; DIAGNOSIS, DIFFERENTIAL; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; DNA REPAIR ENZYMES; HUMANS; IMMUNOHISTOCHEMISTRY; KERATOACANTHOMA; MICROSATELLITE REPEATS; MUIR-TORRE SYNDROME; MUTATION; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS B-RAF; SEBACEOUS GLAND NEOPLASMS;

EID: 84861823414     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3182226a28     Document Type: Review

References (91)

1. Bewtra C. The cost of doing business. Am J Dermatopathol. 2001;33:102.
2. Ponti G, Losi L, Di Gregorio C, et al. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochem-istry. Cancer. 2005;103:1018-1025.
3. Ponti G, Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol. 2005;6: 980-987.
4. Abbas O, Mahalingam M. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm. J Cutan Pathol. 2009;36: 613-619.
5. Eisen DB, Michael DJ. Sebaceous lesions and their associated syndromes: part II. J Am Acad Dermatol. 2009;61:563-580.
6. Muir EG, Bell AJ, Barlow KA. Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face. Br J Surg. 1967;54:191-195.
7. Torre D. Multiple sebaceous tumors. Arch Dermatol. 1968;98:549-551.
8. Ponti G, Losi L, Pedroni M, et al. Value of MLH1 and MSH2 Mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas. J invest Dermatol. 2006;126:2302-2307.
9. Cohen PR, Kohn SR, Kurzrock R. Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med. 1991;90: 606-613.
10. Schwartz RA, Goldberg DJ, Mahmood F, et al. The Muir-Torre syndrome: a disease of sebaceous and colonic neoplasms. Dermatologica. 1989;178: 23-28.
11. Coldron J, Reid I. Muir-Torre syndrome. J R Coll Surg Edinb. 2001;46: 178-179.
12. Finan MC, Connolly SM. Sebaceous gland tumors and systemic disease: a clinicopathologic analysis. Medicine (Baltimore). 1984;63:232-242.
13. Akhtar S, Oza KK, Khan SA, et al. Muir-Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature. J Am Acad Dermatol. 1999;41:681-686.
14. Lynch HT, Lynch PM, Pester J, et al. The cancer family syndrome. Rare cutaneous phenotypic linkage of Torre's syndrome. Arch Intern Med. 1981;141:607-611.
15. Entius ME, Keller JJ, Drillenburg P, et al. Microsatellite instability and Expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome. Clin Cancer Res. 2000;6:1784-1789.
16. Zhang J, Lindroos A, Ollila S, et al. Gene conversion is a frequent mechanism of inactivation of the Wild-type Allele in cancers from MLH1/MSH2 deletion carriers. Cancer Res. 2006;66:659-664.
17. Honchel R, Halling KC, Schaid DJ, et al. Microsatellite instability in Muir-Torre syndrome. Cancer Res. 1994;54:1159-1163.
18. Tanyi M, Olasz J, Lukacs G, et al. A new mutation in Muir-Torre syndrome associated with familial transmission of different gastrointestinal adenocarcinomas. Eur J Surg Oncol. 2009;35:1128-1130.
19. Morales-Burgos A, Sánchez JL, Figueroa LD, et al. MSH-2 and MLH-1 protein expression in Muir Torre syndrome-related and sporadic sebaceous neoplasms. P R Health Sci J. 2008;27:322-327.
20. Schwartz RA, Torre DP. The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol. 1995;33:90-104.
21. Popnikolov NK, Gatalica Z, Colome-Grimmer MI, et al. Loss of mismatch repair proteins in sebaceous gland tumors. J Cutan Pathol. 2003;30:178-184.
22. Kruse R, Rutten A, Schweiger N, et al. Frequency of microsatellite instability in unselected sebaceous gland neoplasias and hyperplasias. J Invest Dermatol. 2003;120:858-864.
23. Chhibber V, Dresser K, Mahalingam M. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome. Mod Pathol. 2008;21:159-164.
24. Cesinaro AM, Ubiali A, Sighinolfi P, et al. Mismatch repair proteins expression and microsatellite instability in skin lesions with sebaceous differentiation: a study in different clinical subgroups with and without extracutaneous cancer. Am J Dermatopathol. 2007;29:351-358.
25. Sciallis GF, Winkelmann RK. Multiple sebaceous adenomas and gastrointestinal carcinoma. Arch Dermatol. 1974;110:913-916.
26. Eisen DB, Michael DJ. Sebaceous lesions and their associated syndromes: part I. J Am Acad Dermatol. 2009;61:549-562.
27. Schwartz RA. Keratoacanthoma.J Am Acad Dermatol. 1994;30:1-22.
28. Pinkus H. Pathobiology of the pilary complex. Jap J Dermatol (Series B). 1967;77:304-330.
29. Rulon DB, Helwig EB. Cutaneous sebaceous neoplasms. Cancer. 1974; 33:82-102.
30. Housholder MS, Zeligman I. Sebaceous neoplasms associated with visceral carcinomas. Arch Dermatol. 1980;116:61-64.
31. Banse-Kupin L, Morales A, Barlow M. Torre's syndrome: report of two cases and review of the literature. J Am Acad Dermatol. 1984;10:803-817.
32. Graham R, McKee P, McGibbon D, et al. Torre-Muir syndrome. An association with isolated sebaceous carcinoma. Cancer. 1985;55:2868-2873.
33. Jacobs DM, Sandles LG, Leboit PE. Sebaceous carcinoma arising from Bowen's disease of the vulva. Arch Dermatol. 1986;122:1191-1193.
34. Schwartz RA, Goldberg DJ, Mahmood F, et al. The Muir-Torre syndrome: a disease of sebaceous and colonic neoplasms. Dermatologica. 1989;178: 23-28.
35. Rothenberg J, Lambert WC, Vail JT Jr, et al. The Muir-Torre (Torre's) syndrome: the significance of a solitary sebaceous tumor. J Am Acad Dermatol. 1990;23:638-640.
36. Jakobiec FA. Sebaceous adenoma of the eyelid and visceral malignancy. Am J Ophthalmol. 1974;78:952-960.
37. Singh RS, Grayson W, Redston M, et al. Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia. Am J Surg Pathol. 2008;32:936-942.
38. Lynch HT, Smyrk T. Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer. 1996;78:1149-1167.
39. Stoebner PE, Fabre C, Delfour C, et al. Solitary subungual keratoacan-thoma arising in an MSH2 germline mutation carrier: confirmation of a relationship by immunohistochemical analysis. Dermatology. 2009;219: 174-178.
40. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338:1481-1487.
41. Vasen HF, Möslein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut. 2008;57: 704-713.
42. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst. 1997;89:1758-1762.
43. Nyström-Lahti M, Kristo P, Nicolaides NC, et al. Founding mutations and Alu-mediated recombination in hereditary colon cancer. Nat Med. 1995;1: 1203-1206.
44. Domingo E, Laiho P, Ollikainen M, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet. 2004;41:664-668.
45. Mathiak M, Rutten A, Mangold E, et al. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test. Am J Surg Pathol. 2002;26:338-343.
46. Kruse R, Ruzicka T. DNA mismatch repair and the significance of a sebaceous skin tumor for visceral cancer prevention. Trends Mol Med. 2004;10:136-141.
47. Machin P, Catasus L, Pons C, et al. Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors for patient of Muir-Torre syndrome. J Cutan Pathol. 2002;29:415-420.
48. Mangold E, Pagenstrecher C, Leister M, et al. A genotype-phenotype correlation in HNPCC: strong predominance of MSH-2 mutations in 41 patients with Muir-Torre Syndrome. J Med Genet. 2004;41:567-572.
49. Marazza G, Masouye I, Taylor S, et al. An illustrative case of Muir-Torre Syndrome. Arch Dermatol. 2006;142:1039-1042.
50. Arnold A, Payne S, Fisher S, et al. An individual with Muir-Torre syndrome found to have a pathogenic MSH6 gene mutation. Fam Cancer. 2007;6:317-321.
51. Mangold E, Rahner N, Friedrichs N, et al. MSH6 mutation in Muir-Torre syndrome: could this be a rare finding? Br J Dermatol. 2007;156: 158-162.
52. Jones B, Oh C, Mangold E, et al. Muir-Torre syndrome: diagnostic and screening guidelines. Australas J Dermatol. 2006;47:266-269.
53. Iaccarino I, Palombo F, Drummond J, et al. MSH6, a Saccharomyces cerevisiae protein that binds to mismatches as a heterodimer with MSH2. Curr Biol. 1996;6:484-486.
54. de Wind N, Dekker M, Claij N, et al. HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions. Nat Genet. 1999;23:359-362.
55. Edelmann W, Yang K, Umar A, et al. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell. 1997;91:467-477.
56. Marra G, Iaccarino I, Lettieri T, et al. Mismatch repair deficiency associated with overexpression of the MSH3 gene. Proc Natl Acad Sci USA. 1998;95:8568-8573.
57. Chang DK, Ricciardiello L, Goel A, et al. Steady-state regulation of the human DNA mismatch repair system. J Biol Chem. 2000;275: 18424-18431.
58. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008;10:293-300.
59. de Jong AE, van Puijenbroek M, Hendriks Y, et al. Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004;10:972-980.
60. Salahshor S, Koelble K, Rubio C, et al. Microsatellite Instability and hMLH1 and hMSH2 expression analysis in familial and sporadic colorectal cancer. Lab Invest. 2001;81:535-541.
61. Peltomäki P, Vasen H. Mutations associated with HNPCC predisposition\update of ICG-HNPCC/INSiGHT mutation database. Dis Markers. 2004; 20:269-276.
62. Doxey BW, Kuwada SK, Burt RW. Inherited polyposis syndromes: molecular mechanisms, clinicopathology, and genetic testing. Clin Gastroenterol Hepatol. 2005;3:633-641.
63. de la Chapelle A. Microsatellite instability. N Engl J Med. 2003;349: 209-210.
64. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med. 2003;138: 560-570.
65. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248-5257.
66. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993;260:816-819.
67. Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363:558-561.
68. Kolodner RD, Tytell JD, Schmeits JL, et al. Germ-line msh6 mutations in colorectal cancer families. Cancer Res. 1999;59:5068-5074.
69. Wu Y, Berends MJ, Mensink RG, et al. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low micro-satellite instability with MSH6 germline mutations. Am J Hum Genet. 1999;65:1291-1298.
70. Verma L, Kane MF, Brassett C, et al. Mononucleotide microsatellite instability and germline MSH6 mutation analysis in early onset colorectal cancer. J Med Genet. 1999;36:678-682.
71. Kets CM, van Krieken JH, Hebeda KM, et al. Very low prevalence of germline MSH6 mutations in hereditary non-polyposis colorectal cancer suspected patients with colorectal cancer without microsatellite instability. Br J Cancer. 2006;95:1678-1682.
72. Kruse R, Rutten A, Lamberti C, et al. Muir Torre Phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet. 1998;63:63-70.
73. Debniak T, Kurzawski G, Gorski B, et al. Value of pedigree/clinical data, immunohistochemistry and microsatellite instability analyses in reducing the cost of determining hMLH1 and hMSH2 gene mutations in patients with colorectal cancer. Eur J Cancer. 2000;36:49-54.
74. Cunningham JM, Kim CY, Christensen ER, et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet. 2001;69:780-790.
75. Scartozzi M, Bianchi F, Rosati S, et al. Mutations of hMLH1 and hMSH2 in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with microsatellite instability and abnormalities of mismatch repair protein expression. J Clin Oncol. 2002;20: 1203-1208.
76. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352:1851-1860.
77. Piñol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005;293:1986-1994.
78. Southey MC, Jenkins MA, Mead L, et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol. 2005;23:6524-6532.
79. Engel C, Forberg J, Holinski-Feder E, et al. Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. Int J Cancer. 2006;118:115-122.
80. Niessen RC, Berends MJ, Wu Y, et al. Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer. Gut. 2006;55:1781-1788.
81. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med. 2006;354:2751-2763.
82. Gras E, Catasus L, Argüelles R, et al. Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mono-nucleotide repeat microsatellites in ovarian tumors. Cancer. 2001;92: 2829-2836.
83. Auclair J, Vaissière T, Desseigne F, et al. Intensity-dependent constitutional MLH1 promoter methylation leads to early onset of colorectal cancer by affecting both alleles. Genes Chromosomes Cancer. 2011;50: 178-185.
84. Vasavi M, Kiran V, Ravishankar B, et al. Microsatellite instability analysis and its correlation with hMLH1 repair gene hypermethylation status in esophageal pathologies including cancers. Cancer Biomark. 2010;7:1-10.
85. Arai T, Kasahara I, Sawabe M, et al. Role of methylation of the hMLH1 gene promoter in the development of gastric and colorectal carcinoma in the elderly. Geriatr Gerontol Int. 2010;10:S207-S212.
86. Yoo KH, Park YK, Kim HS, et al. Epigenetic inactivation of HOXA5 and MSH2 gene in clear cell renal cell carcinoma. Pathol Int. 2010;60:661-666.
87. Kruse R, Lamberti C, Wang Y, et al. Is the mismatch repair deficient type of Muir-Torre syndrome confined to mutations in the hMSH2 gene? Hum Genet. 1996;98:747-750.
88. Czerninski R, Krichevsky S, Ashhab Y, et al. Promoter hypermethylation of mismatch repair genes, hMLH1 and hMSH2 in oral squamous cell carcinoma. Oral Dis. 2009;15:206-213.
89. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
90. Ponti G, Venesio T, Losi L, et al. BRAF mutations in multiple sebaceous hyperplasias of patients belonging to MYH-associated polyposis pedigrees. J Invest Dermatol. 2007;127:1387-1391.
91. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999;116:1453-1456.